Notice of Exclusive License Agreement for IgG-Degrading Drug Assets with Biohaven

Agreement Overview

Ono Pharmaceutical Co., Ltd. has entered into an exclusive license agreement with Biohaven for IgG-degrading drug assets (BHV-1300, BHV-1310, BHV-1320) for development and commercialization in Japan, Korea, Taiwan and ASEAN countries. Under the agreement, Ono Pharmaceutical will pay an upfront payment of 0.8 hundred million USD, milestone payments of 0.2 hundred million USD based on progress, and approximately 20% of sales as royalties to Biohaven. Ono Pharmaceutical will be responsible for conducting clinical trials, obtaining regulatory approvals, and commercial sales. The most advanced asset, BHV-1300, is currently in global Phase 3 trials targeting Graves' disease.

Future Impact and Outlook

This collaboration strengthens the medium- to long-term strategy in the immunology and inflammation field, creating opportunities to provide new treatment options for patients with Graves' disease and to expand the market. The impact on consolidated results for the fiscal year ending March 2027 is expected to be minimal; further disclosures will be made as required. By combining Biohaven's technological capabilities with Ono Pharmaceutical's Asian market development strength, the parties aim to accelerate clinical development and commercialization.